Last reviewed 2026-04-20 · How we verify

Stimovul (EPIMESTROL)

Phase 2 active Small molecule

Stimovul (generic name: EPIMESTROL) is a epimestrol drug. It is currently in Phase 2 development.

Stimovul is thought to work by interacting with a specific molecular target, although its exact mechanism of action is currently unknown.

Stimovul (EPIMESTROL) is a small molecule drug in the epimestrol class, but its target and exact mechanism of action are unknown. It is not clear if it is FDA-approved or commercially available. The drug's pharmacokinetic properties, such as half-life and bioavailability, are also unknown. As a result, there is limited information available on its approved indications, generic manufacturers, or patent status. Further research is needed to fully understand Stimovul's characteristics and clinical applications.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EPIMESTROL
Drug class	epimestrol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Stimovul is a key that fits into one of those locks. When it binds to the lock, it can either turn the lock on or off, depending on the type of lock and the key's shape. This interaction can affect how cells behave and respond to signals, but the exact details of how Stimovul works are still being studied.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Stimovul CI brief — competitive landscape report
Stimovul updates RSS · CI watch RSS

Frequently asked questions about Stimovul

What is Stimovul?

Stimovul (EPIMESTROL) is a epimestrol drug.

How does Stimovul work?

Stimovul is thought to work by interacting with a specific molecular target, although its exact mechanism of action is currently unknown.

What is the generic name of Stimovul?

EPIMESTROL is the generic (nonproprietary) name of Stimovul.

What drug class is Stimovul in?

Stimovul belongs to the epimestrol class. See all epimestrol drugs at /class/epimestrol.

What development phase is Stimovul in?

Stimovul is in Phase 2.

Drug class: All epimestrol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing